MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) Raised to Strong-Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) from a hold rating to a strong-buy rating in a research note issued to investors on Thursday, Zacks.com reports. Zacks Investment Research currently has $38.00 price target on the stock.

According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany. “

Several other research firms have also commented on MOR. Barclays reissued an equal weight rating on shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 in a report on Wednesday, May 13th. Royal Bank of Canada lowered shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 from an outperform rating to a sector perform rating in a report on Thursday, June 25th. Finally, HSBC raised shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 from a reduce rating to a hold rating in a report on Tuesday, May 12th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of $38.00.

NYSEARCA:MOR opened at $32.43 on Thursday. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has a 52 week low of $18.21 and a 52 week high of $37.96. The firm’s 50-day simple moving average is $31.82 and its 200 day simple moving average is $29.90.

MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Further Reading: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR)

Receive News & Ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 and related companies with MarketBeat.com's FREE daily email newsletter.